Transfusion-dependent thalassaemia: a new era

Vasili Berdoukas and Bernadette Modell
Med J Aust 2008; 188 (2): . || doi: 10.5694/j.1326-5377.2008.tb01523.x
Published online: 21 January 2008

With three iron chelating agents now available, management options have substantially increased

Outcomes in patients with thalassaemia major have been revolutionised over the past 50 years. Without transfusions, death usually occurred in the first decade of life. In the 1950s, transfusions were given to manage the symptoms of anaemia, which resulted in increased survival but significant morbidity. In the 1960s, regular blood transfusions were introduced to maintain relatively high mean haemoglobin levels in order to suppress the production of abnormal red cells in the bone marrow. This permitted good quality of life in childhood, but led to cardiac death from transfusional iron overload at a mean age of 18 years.1 Fortunately, the parenteral iron chelating agent desferrioxamine was also introduced in the 1960s, and its use to control iron load led to improved survival2 and reduced morbidity.3 Nevertheless, the difficult treatment regimen (subcutaneous infusion for 8–12 hours per night, 3–7 nights per week) resulted in poor compliance. Cardiomyopathy remains the most common cause of premature death in patients with thalassaemia,3 even in well chelated patients.4

  • 1 Department of Medicine, Lefkos Stavros Hospital, Athens, Attika, Greece.
  • 2 Centre for Health Informatics and Multiprofessional Education, University College London, London, UK.


Competing interests:

Vasili Berdoukas is a consultant for ApoPharma, the company that markets deferiprone, and he has a confidentiality agreement with Novartis for the development of deferasirox. He has also received travel assistance and honoraria for attending conferences and for presentations at such conferences.

  • 1. Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed) 1982; 284: 1081-1084.
  • 2. Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet 2000; 355: 2051-2052.
  • 3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
  • 4. Berdoukas V, Dakin C, Freeman A, et al. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Haematologica 2005; 90: 685-686.
  • 5. Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92: 131-132.
  • 6. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543-547.
  • 7. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-3744.
  • 8. Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006; 134: 438-444.
  • 9. Tsironi M, Deftereos S, Andriopoulos P, et al. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74: 84-85.
  • 10. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
  • 11. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 2006; 91: 1187-1192.
  • 12. Kidson-Gerber GL, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust 2008; 188: 72-75. <eMJA full text>
  • 13. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.